Effective management of lower urinary tract dysfunction in idiopathic Parkinson's disease

被引:28
作者
Kapoor, Sona [1 ]
Bourdoumis, Andreas [1 ]
Mambu, Lewis [1 ]
Barua, Jayanta [1 ]
机构
[1] Barking Havering & Redbridge Univ Teaching Hosp N, Dept Urol, King George Hosp, Ilford IG3 8YB, Essex, England
关键词
bladder dysfunction; management; multiple system atrophy; parkinsonism; urinary symptoms; MULTIPLE SYSTEM ATROPHY; NEUROGENIC DETRUSOR OVERACTIVITY; QUESTIONNAIRE-BASED ASSESSMENT; BLADDER DYSFUNCTION; VOIDING DYSFUNCTION; SYMPTOMS; TOLTERODINE; PREVALENCE; STIMULATION; OXYBUTYNIN;
D O I
10.1111/j.1442-2042.2012.03220.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
100201 [内科学]; 100221 [泌尿外科学];
摘要
Parkinson's disease, also known as paralysis agitans, is a progressive degenerative disorder of the central nervous system, with onset usually between the ages of 50 and 65?years, and is associated with loss of dopaminergic neurons in the subsantia nigra and the presence of Lewy bodies. It is characterized by the triad of resting tremor, muscular rigidity and bradykinesia. Often-accompanying abnormalities include disorders of equilibrium, posture and autonomic function, including micturition. Symptoms from the lower urinary tract add a significant comorbidity factor in these patients. The incidence and prevalence of lower urinary tract dysfunction rise with increasing progression of the underlying neurological disease. They present a troublesome and difficult to treat health issue with a profound impact on the patient's quality of life. Storage symptoms seem to predominate. In the long term, renal function might be compromised, mainly as a result of elevated intravesical pressure. Various conservative, minimally-invasive and surgical treatment options are available to prevent harmful sequelae, and to improve the quality of life of these patients. We present an overview of current and prospective treatment strategies.
引用
收藏
页码:79 / 84
页数:6
相关论文
共 47 条
[1]
Treatment of overactive bladder: Other drug mechanisms [J].
Andersson, KE .
UROLOGY, 2000, 55 (5A) :51-57
[2]
Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: A pooled analysis [J].
Appell, RA .
UROLOGY, 1997, 50 (6A) :90-96
[3]
Assessment of voiding dysfunction in Parkinson's disease by the international prostate symptom score [J].
Araki, I ;
Kuno, S .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2000, 68 (04) :429-433
[4]
Voiding dysfunction and Parkinson's disease: Urodynamic abnormalities and urinary symptoms [J].
Araki, I ;
Kitahara, M ;
Oida, T ;
Kuno, S .
JOURNAL OF UROLOGY, 2000, 164 (05) :1640-1643
[5]
GENITOURINARY DYSFUNCTION IN MULTIPLE SYSTEM ATROPHY - CLINICAL-FEATURES AND TREATMENT IN 62 CASES [J].
BECK, RO ;
BETTS, CD ;
FOWLER, CJ .
JOURNAL OF UROLOGY, 1994, 151 (05) :1336-1341
[6]
Stages in the development of Parkinson's disease-related pathology [J].
Braak, H ;
Ghebremedhin, E ;
Rüb, U ;
Bratzke, H ;
Del Tredici, K .
CELL AND TISSUE RESEARCH, 2004, 318 (01) :121-134
[7]
Effects of Inhibitory rTMS on Bladder Function in Parkinson's Disease Patients [J].
Brusa, Livia ;
Agro, Enrico Finazzi ;
Petta, Filomena ;
Sciobica, Francesco ;
Torriero, Sara ;
Lo Gerfo, Emanuele ;
Lani, Cesare ;
Stanzione, Paolo ;
Koch, Giacomo .
MOVEMENT DISORDERS, 2009, 24 (03) :445-448
[8]
Burn DJ, 2001, J CLIN PATHOL-MOL PA, V54, P419
[9]
Urinary symptoms in Parkinson's disease - Prevalence and associated factors [J].
Campos-Sousa, RN ;
Quagliato, E ;
da Silva, BB ;
De Carvalho, RM ;
Ribeiro, SC ;
de Carvalho, DFM .
ARQUIVOS DE NEURO-PSIQUIATRIA, 2003, 61 (2B) :359-363
[10]
How to recognize patients with parkinsonism who should not have urological surgery [J].
Chandiramani, VA ;
Palace, J ;
Fowler, CJ .
BRITISH JOURNAL OF UROLOGY, 1997, 80 (01) :100-104